SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (20387)4/12/1999 8:19:00 AM
From: blankmind  Respond to of 23519
 
Edderd - you're 100% right

- MUSE isn't the end of Vivus's story - instead, it's just the first chapter

- I really want to hear more about the female cream



To: Edderd who wrote (20387)4/12/1999 9:15:00 AM
From: Mkilloran  Respond to of 23519
 
Edderd...Conf call is April 21st...



To: Edderd who wrote (20387)4/12/1999 12:37:00 PM
From: VLAD  Read Replies (2) | Respond to of 23519
 
Ed,

Don't forget this was the EUA meeting. MUSE to this date has only been launched in England, Sweden and Switzerland as far as Europe goes. It is important that the European urologists know about MUSE etc. It is even more important that AstraZeneca gets to those European PCPs.

Your comments certainly apply to the USA. We need that marketing partner to start detailing the PCP in the US. SALES SALES SALES!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News